Baxter International Inc. Files 10-Q for Q2 2024
Ticker: BAX · Form: 10-Q · Filed: Aug 6, 2024 · CIK: 10456
Sentiment: neutral
Topics: 10-Q, quarterly-report, healthcare
Related Tickers: BAX
TL;DR
BAX Q2 2024 10-Q filed. Check financials.
AI Summary
Baxter International Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's financial performance for the period and its ongoing operations are detailed in this 10-Q filing. Specific financial figures and operational highlights are available within the document.
Why It Matters
This filing provides investors and analysts with the latest financial and operational details for Baxter International Inc., crucial for understanding the company's performance and future outlook.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing financial updates, not indicating immediate or significant new risks.
Key Numbers
- 2024 Q2 — Reporting Period (Quarterly filing for the second quarter of 2024.)
- 1231 — Fiscal Year End (Indicates the end of the company's fiscal year.)
Key Players & Entities
- BAXTER INTERNATIONAL INC (company) — Filer
- 20240630 (date) — Period of Report
- 20240806 (date) — Filed as of Date
- DEERFIELD, IL (location) — Business Address
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, indicating the second quarter of 2024.
When was this 10-Q filing submitted?
The filing was submitted on 20240806.
What is Baxter International Inc.'s primary business classification?
Baxter International Inc. is classified under SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841].
Where is Baxter International Inc. headquartered?
The company's business address is located at ONE BAXTER PKWY, DEERFIELD, IL 60015.
What is the ticker symbol or exchange information mentioned?
The filing mentions trading on the New York Stock Exchange (exch:XNYS) and Chicago Stock Exchange (exch:XCHI).
Filing Stats: 5,022 words · 20 min read · ~17 pages · Grade level 17.6 · Accepted 2024-08-06 07:20:53
Key Financial Figures
- $1.00 — ange on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exc
Filing Documents
- bax-20240630.htm (10-Q) — 1989KB
- bax-20240630xex311.htm (EX-31.1) — 10KB
- bax-20240630xex312.htm (EX-31.2) — 9KB
- bax-20240630ex321.htm (EX-32.1) — 4KB
- bax-20240630xex322.htm (EX-32.2) — 4KB
- 0001628280-24-034965.txt ( ) — 10946KB
- bax-20240630.xsd (EX-101.SCH) — 64KB
- bax-20240630_cal.xml (EX-101.CAL) — 104KB
- bax-20240630_def.xml (EX-101.DEF) — 347KB
- bax-20240630_lab.xml (EX-101.LAB) — 798KB
- bax-20240630_pre.xml (EX-101.PRE) — 577KB
- bax-20240630_htm.xml (XML) — 2067KB
Financial Statements (unaudited)
Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Loss 3 Condensed Consolidated Statements of Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 51 Item 4.
Controls and Procedures
Controls and Procedures 52 PART II. OTHER INFORMATION 53 Item 1.
Legal Proceedings
Legal Proceedings 53
Risk Factors
Item 1A. Risk Factors 53 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53
Other Information
Item 5. Other Information 53 Item 6. Exhibits 54 Signature 55
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements Baxter International Inc. Condensed Consolidated Balance Sheets (unaudited) (in millions, except share information) June 30, 2024 December 31, 2023 Current assets: Cash and cash equivalents $ 2,095 $ 3,194 Accounts receivable, net of allowances of $ 123 in 2024 and $ 129 in 2023 2,639 2,690 Inventories 2,985 2,824 Prepaid expenses and other current assets 874 892 Total current assets 8,593 9,600 Property, plant and equipment, net 4,314 4,433 Goodwill 6,001 6,514 Other intangible assets, net 5,741 6,079 Operating lease right-of-use assets 524 524 Other non-current assets 1,139 1,126 Total assets $ 26,312 $ 28,276 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 2,468 $ 2,668 Accounts payable 1,251 1,241 Accrued expenses and other current liabilities 2,412 2,594 Total current liabilities 6,131 6,503 Long-term debt and finance lease obligations, less current portion 10,436 11,130 Operating lease liabilities 439 438 Other non-current liabilities 1,598 1,737 Total liabilities 18,604 19,808 Commitments and contingencies Equity: Common stock, $ 1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2024 and 2023 683 683 Common stock in treasury, at cost, 173,429,843 shares in 2024 and 175,861,893 shares in 2023 ( 11,104 ) ( 11,230 ) Additional contributed capital 6,353 6,389 Retained earnings 15,539 16,114 Accumulated other comprehensive loss ( 3,828 ) ( 3,554 ) Total Baxter stockholders' equity 7,643 8,402 Noncontrolling interests 65 66 Total equity 7,708 8,468 Total liabilities and equity $ 26,312 $ 28,276 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Baxter International Inc. Condensed Consolidated Statements of Loss (unaudited) (in millions, except per share data) Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Net sales $ 3,812 $ 3,707 $ 7,404 $ 7